Abstract
Dispeptik yakınmaların sık görülmesi nedeniyle diyabet hastaları reçeteli ya da reçetesiz olarak proton pompa inhibitörleri PPİ grubu ilaçları sık olarak kullanırlar. Farklı hastalıklar nedeniyle çeşitli ilaç gruplarının bir arada kullanılması, azalan sitokrom p450 enzim aktivitesi nedeniyle özellikle yaşlı hastalarda, ilaç-ilaç etkileşimi ve ilaç etkisinin değişmesi riskini artırmaktadır. Bu vaka sunumunda 82 yaşında diyabetik hastada omeprazol ve gliklazid ilaç etkileşimine bağlı gelişen hipoglisemi olgusu sunuldu
References
- Boj-Carceller D. Proton pump inhibitors: impact on gluco- se metabolism. Endocrine 2013;43:22-32.
- Mefford IN, Wade EU. Proton pump inhibitors as a tre- atment method for type II diabetes. Med Hypotheses 2009;73:29-32.
- Boj-Carceller D, Bocos-Terraz P, Moreno-Vernis M, et al. Are proton pump inhibitors a new antidiabetic drug? A cross sectional study. World J Diabetes 2011;2:217-20.
- Crouch MA, Mefford IN, Wade EU. Proton pump inhibitör therapy associated with lower glycosylated hemoglobin le- vels in type 2 diabetes. J Am Board Fam 2012;25:50-4.
- Phadatare PD, Chandrashekhar VM. Influence of esomep- razole on hypoglycemic activity of oral antidiabetic agents in rats and rabbits. Mol Cell Biochem 2011;354:135-40.
- Kumar V, Venakat Rao N, Ramachandra Setty S. Influence of omeprazole on hypoglycemic activity of glibenclamide and tolbutamide normal albino rabbits. Acta Pharm Turc 2000;42:135-8.
Abstract
Patients with diabetes mellitus frequently use prescription or nonprescription proton pump inhibitors PPI since they commonly have dyspeptic complaints. Simultaneous use of various drug groups due to presence of different diseases in the same patient increases the risk of drug-to-drug interaction and change of drug effect secondary to decreased cytochrome p450 enzyme activity, especially in elderly patients. A case of an 82-year-old diabetic patient who developed hypoglycemia secondary to a drug interaction of omeprazole and gliclazide
References
- Boj-Carceller D. Proton pump inhibitors: impact on gluco- se metabolism. Endocrine 2013;43:22-32.
- Mefford IN, Wade EU. Proton pump inhibitors as a tre- atment method for type II diabetes. Med Hypotheses 2009;73:29-32.
- Boj-Carceller D, Bocos-Terraz P, Moreno-Vernis M, et al. Are proton pump inhibitors a new antidiabetic drug? A cross sectional study. World J Diabetes 2011;2:217-20.
- Crouch MA, Mefford IN, Wade EU. Proton pump inhibitör therapy associated with lower glycosylated hemoglobin le- vels in type 2 diabetes. J Am Board Fam 2012;25:50-4.
- Phadatare PD, Chandrashekhar VM. Influence of esomep- razole on hypoglycemic activity of oral antidiabetic agents in rats and rabbits. Mol Cell Biochem 2011;354:135-40.
- Kumar V, Venakat Rao N, Ramachandra Setty S. Influence of omeprazole on hypoglycemic activity of glibenclamide and tolbutamide normal albino rabbits. Acta Pharm Turc 2000;42:135-8.
Details
| Primary Language | Turkish |
|---|---|
| Journal Section | Case Report |
| Authors | |
| Publication Date | September 1, 2017 |
| Published in Issue | Year 2017 Volume: 27 Issue: 3 |
The Journal of General Medicine is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY NC).